HSV-1 and 2 infections are common across the globe with recent prevalence estimates of 3709 million cases of HSV-1 (including 140 million cases of genital HSV-1 infection) and 417 million cases of HSV-2 infection. Women are at higher risk and acquire HSV-2 at a younger age than men. Prevalent HSV-2 increases risk of HIV acquisition 2-3 fold. An estimated 14,000 infants contract neonatal HSV infection each year, a frequently fatal disease. The risk of transmission to the newborn is highest if a woman acquires genital herpes toward the end of pregnancy. Current standard of care is to treat women with recurrent genital herpes with suppressive antivirals toward the end of pregnancy; although this approach may reduce cesarean sections, it has had no effect on the incidence of neonatal herpes. The risk of neonatal herpes in infants born to women with established infection is very low. Implementation of control strategies is hampered by lack of evidence-based interventions. Patient management is limited by lack of commercial accurate serologic assays; only partial effectiveness of antiviral for HSV in reducing the risk for sexual transmission, and persistent stigma associated with this infection. While resistance to currently available therapies occurs almost exclusively among immunocompromised patients, alternative therapies for such patients are inadequate and no new drugs have been developed for several decades. A number of vaccines are in development, mostly aimed at therapeutic use. Lack of knowledge about immune correlates of protection complicates the evaluation of candidate vaccine products. However, elimination of HSV infections is likely to be achieved only through prophylactic immunization.